GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » Beneish M-Score

Arvinas (Arvinas) Beneish M-Score : -1.36 (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Arvinas Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.36 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Arvinas's Beneish M-Score or its related term are showing as below:

ARVN' s Beneish M-Score Range Over the Past 10 Years
Min: -3.53   Med: -1.35   Max: 75.67
Current: -1.36

During the past 8 years, the highest Beneish M-Score of Arvinas was 75.67. The lowest was -3.53. And the median was -1.35.


Arvinas Beneish M-Score Historical Data

The historical data trend for Arvinas's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arvinas Beneish M-Score Chart

Arvinas Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -1.35 -2.45 - -2.06 -2.61

Arvinas Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.36 -2.60 -0.93 -2.61 -1.36

Competitive Comparison of Arvinas's Beneish M-Score

For the Biotechnology subindustry, Arvinas's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arvinas's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Arvinas's Beneish M-Score falls into.



Arvinas Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Arvinas for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.9089+0.528 * 1+0.404 * 0.932+0.892 * 0.5193+0.115 * 0.8859
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.2752+4.679 * -0.000495-0.327 * 0.8204
=-1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $7.10 Mil.
Revenue was 25.3 + -43.1 + 34.6 + 54.5 = $71.30 Mil.
Gross Profit was 25.3 + -43.1 + 34.6 + 54.5 = $71.30 Mil.
Total Current Assets was $1,190.30 Mil.
Total Assets was $1,212.60 Mil.
Property, Plant and Equipment(Net PPE) was $12.40 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.70 Mil.
Selling, General, & Admin. Expense(SGA) was $99.60 Mil.
Total Current Liabilities was $240.80 Mil.
Long-Term Debt & Capital Lease Obligation was $1.10 Mil.
Net Income was -69.4 + -154.8 + -64 + -66.6 = $-354.80 Mil.
Non Operating Income was 0 + -0.1 + 0 + 0 = $-0.10 Mil.
Cash Flow from Operations was -97.5 + -83.1 + -84.8 + -88.7 = $-354.10 Mil.
Total Receivables was $4.70 Mil.
Revenue was 32.5 + 37.8 + 33.2 + 33.8 = $137.30 Mil.
Gross Profit was 32.5 + 37.8 + 33.2 + 33.8 = $137.30 Mil.
Total Current Assets was $1,148.20 Mil.
Total Assets was $1,175.80 Mil.
Property, Plant and Equipment(Net PPE) was $17.30 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.80 Mil.
Selling, General, & Admin. Expense(SGA) was $84.30 Mil.
Total Current Liabilities was $282.90 Mil.
Long-Term Debt & Capital Lease Obligation was $3.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7.1 / 71.3) / (4.7 / 137.3)
=0.099579 / 0.034232
=2.9089

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(137.3 / 137.3) / (71.3 / 71.3)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1190.3 + 12.4) / 1212.6) / (1 - (1148.2 + 17.3) / 1175.8)
=0.008164 / 0.00876
=0.932

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=71.3 / 137.3
=0.5193

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(7.8 / (7.8 + 17.3)) / (6.7 / (6.7 + 12.4))
=0.310757 / 0.350785
=0.8859

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(99.6 / 71.3) / (84.3 / 137.3)
=1.396914 / 0.613984
=2.2752

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.1 + 240.8) / 1212.6) / ((3 + 282.9) / 1175.8)
=0.199489 / 0.243154
=0.8204

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-354.8 - -0.1 - -354.1) / 1212.6
=-0.000495

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Arvinas has a M-score of -1.36 signals that the company is likely to be a manipulator.


Arvinas Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Arvinas's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Arvinas (Arvinas) Business Description

Traded in Other Exchanges
N/A
Address
395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Executives
Ronald Peck officer: Chief Medical Officer C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal director 60 LEVERONI COURT, NOVATO CA 94949
Ian Taylor officer: Senior Vice President, Biology C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston director, officer: President and CEO C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy officer: Chief Financial Officer 322 EAST MAIN STREET, BRANFORD CT 06405
Everett Cunningham director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
David K Loomis officer: Chief Accounting Officer C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
John D Young director C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe director, 10 percent owner C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon director C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr. director C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon director
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139